ArticleFrontiers in psychology2022
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals.
Article in Frontiers in psychology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.International journal of molecular sciences · 2026Pooled it
- Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.Translational psychiatry · 2025Pooled it
- Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026Review
- Discordance Between Spatial and Population Correlations From Human Brain Imaging Data.Human brain mapping · 2025Article
- Embracing change: impermanence acceptance mediates differences in death processing between long-term ayahuasca users and non-users.Psychopharmacology · 2025Article
- Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney's lesions.European archives of psychiatry and clinical neuroscience · 2024Article
- Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.Pharmacology & therapeutics · 2024Review
- The Relationship Between Changes in Mindfulness and Subsequent Changes in Well-Being Following Psychedelic Use: Prospective Cohort Study.JMIR formative research · 2024Article
- The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects.Npj mental health research · 2024Review
- Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.AJNR. American journal of neuroradiology · 2024Review
- Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.Neuroscience applied · 2024Review
- Self-transcendence accompanies aesthetic chills.PLOS mental health · 2024Article
- Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.Comprehensive psychoneuroendocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT Aim: We evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT Materials and methods: Forty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [ Results: The MAAS score was significantly increased at 3-month follow-up ( Conclusion: We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.